Share This Page
Drug Price Trends for GRALISE
✉ Email this page to a colleague
Average Pharmacy Cost for GRALISE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GRALISE ER 600 MG TABLET | 52427-0806-90 | 10.16990 | EACH | 2025-12-17 |
| GRALISE ER 450 MG TABLET | 52427-0804-60 | 10.14274 | EACH | 2025-12-17 |
| GRALISE ER 900 MG TABLET | 52427-0890-60 | 15.29678 | EACH | 2025-12-17 |
| GRALISE ER 300 MG TABLET | 52427-0803-90 | 10.20325 | EACH | 2025-12-17 |
| GRALISE ER 600 MG TABLET | 52427-0806-90 | 10.17995 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for GRALISE (Methylphenidate Hydrochloride Extended-Release)
Introduction
GRALISE (methylphenidate hydrochloride extended-release) is a pharmaceutical product approved by the FDA primarily for the management of neuropathic pain associated with postherpetic neuralgia (PHN). As a successor and alternative to existing therapies, its market positioning, demand trajectories, and competitive landscape merit close examination. This analysis delineates the current market environment, evaluates growth drivers and challenges, and offers price projections grounded in industry dynamics.
Overview of GRALISE: Product Profile
Initially launched in 2013 by Amedra Pharmaceuticals (later acquired by Mylan, now part of Viatris), GRALISE offers an extended-release formulation of methylphenidate, traditionally recognized as a central nervous system stimulant. Although methylphenidate is predominantly used in ADHD and narcolepsy treatments, GRALISE's application in neuropathic pain signifies a strategic pivot, tapping into the niche PHN management market.
Its unique extended-release formulation improves compliance and dosing convenience for patients with chronic pain. The proof of concept derives from methylphenidate’s modulation of neurological pathways implicated in nerve pain, providing an innovative therapeutic rationale.
Market Dynamics and Drivers
1. Market Size and Potential
The global neuropathic pain market was valued at approximately USD 4.5 billion in 2022, with projections indicating a compound annual growth rate (CAGR) of around 4.2% over the next five years [1]. Within this, postherpetic neuralgia accounts for an estimated USD 1.2 billion segment, given its prevalence—approximately 0.5% to 1% of shingles cases—and chronicity.
GRALISE's niche targets a subset of PHN patients who respond inadequately to first-line agents such as gabapentinoids, tricyclic antidepressants, or opioids. Although its share remains limited as of 2023, increased awareness and off-label use may influence growth.
2. Competitive Landscape
Multiple agents compete within the PHN treatment sphere:
- Gabapentin and Pregabalin: Widely prescribed, generics dominate, pressuring prices.
- Tricyclic Antidepressants: Efficacious but limited by side effects.
- Topicals (Lidocaine patches): Alternative modalities.
- Opioids: Restricted due to regulatory shifts.
The inclusion of GRALISE introduces a methylphenidate-based option distinguished by its extended-release profile. While not yet mainstream, its advantages include targeted pet efficacy and improved dosing schedules.
3. Regulatory and Prescriptive Trends
The expanding emphasis on non-opioid, non-sedating therapies for pain management bodes well for GRALISE adopting a broader prescriptive footprint. However, regulatory scrutiny over central nervous system stimulants necessitates ongoing safety evaluations.
Price Analysis and Historical Pricing Trends
1. Pricing Benchmarking
As a branded product, GRALISE's average wholesale price (AWP) per 30-day supply was approximately USD 600–USD 700 in 2023, notably higher than generics (e.g., gabapentin at USD 20–USD 30/month). This premium reflects its differentiated formulation and specific indication.
2. Relative Market Positioning
Price elasticity studies in chronic pain pharmaceuticals suggest that consumers and prescribers exhibit sensitivity to price, especially when affordable generics are available [2]. GRALISE’s pricing power relies on clinical advantages, niche indication, and formulary positioning.
3. Reimbursement Dynamics
Insurance coverage favors cost-effective therapies. As payers negotiate rebates and discounts, net prices of GRALISE may decline. Mylan/Viatris has implemented rebate strategies to sustain its market share.
Forecasting Price Trajectories (2023-2028)
Considering the market environment and patent/pipeline landscape, the following projections are made:
| Year | Estimated AWP per 30-day supply | Market Drivers | Key Assumptions |
|---|---|---|---|
| 2023 | USD 650 | Initial stabilization; modest adoption | Steady prescriber acceptance; limited competition |
| 2024 | USD 640–USD 670 | Slight price erosion; increased competition from generics | Payer discounting, formulary incorporation |
| 2025 | USD 620–USD 660 | Expanding indication awareness; potential biosimilar entries | Clinical data supporting broader use |
| 2026 | USD 600–USD 640 | Market consolidation; price pressures continue | Patent expirations for competitors; generics intensify competition |
| 2027 | USD 580–USD 620 | Evolving therapeutic landscape | Bioequivalent generics reduce premium positioning |
| 2028 | USD 560–USD 600 | Competitive commoditization | Emphasis on cost containment in pain management |
Note: The downward trend reflects typical pharmaceutical pricing erosion amid generic competition and payer negotiations.
Market Penetration and Revenue Projections
Assuming modest adoption growth, with prescriber uptake increasing from 10,000 patients in 2023 to approximately 50,000 by 2028, revenues can be extrapolated based on per-unit pricing:
- 2023 Revenue Estimate: USD 6.5 million (10,000 patients × USD 650/month × 12 months)
- 2028 Revenue Estimate: USD 360 million (50,000 patients × USD 600/month × 12 months)
These figures rely on assumption of stable compliance rates and consistent prescribing practices. The emphasis remains on the strategic importance of patient segmentation and formularies.
Challenges and Opportunities
Challenges:
- Limited Market Penetration: Currently, GRALISE's niche status limits revenue.
- Pricing Pressure: Generics and biosimilars could dilute premium pricing.
- Regulatory Risks: Off-label claims or safety concerns may impact utilization.
- Competition from Established Therapies: First-line agents continue to dominate, constraining growth.
Opportunities:
- Expanded Indications: Investigating other neuropathic pain conditions.
- Combination Therapy: Co-administration with other analgesics.
- Market Expansion: Penetration into emerging markets with rising chronic pain prevalence.
- Pricing Strategies: Value-based pricing models emphasizing clinical benefits.
Key Takeaways
- Market Positioning: GRALISE occupies a niche in PHN pain management, with growth potential rooted in clinical differentiation and prescriber awareness.
- Pricing Trends: Branded formulations like GRALISE face typical price erosion due to generic competition; initial premium pricing is likely to decline gradually over 3–5 years.
- Revenue Forecasts: With increasing acceptance, revenues could grow significantly, albeit with declining per-unit prices.
- Strategic Focus: Success depends on expanding indications, optimizing formulary access, and differentiating through clinical efficacy.
- Competitive Landscape: As the neuropathic pain market evolves, maintaining a unique value proposition is vital for sustained profitability.
FAQs
1. What is the primary therapeutic use of GRALISE?
GRALISE is approved for the management of neuropathic pain associated with postherpetic neuralgia, providing an extended-release methylphenidate formulation aimed at improving patient compliance.
2. How does GRALISE compare to other PHN treatments?
While traditional therapies like gabapentin and tricyclic antidepressants are first-line treatments, GRALISE offers a potentially targeted, longer-duration option with a novel mechanism, though it remains a niche therapy primarily due to its higher cost and specialized indication.
3. What are the main factors influencing GRALISE’s pricing?
Pricing is driven by its branded status, clinical differentiation, market demand, payer negotiations, and competition from generic formulations of conventional therapies.
4. What are the risks to market growth for GRALISE?
Key risks include increased generic competition, regulatory challenges, off-label safety concerns, and limited awareness among prescribers, potentially curbing market expansion.
5. What strategies could enhance GRALISE’s market share?
Expanding indications, demonstrating clear clinical benefits through rigorous trials, enhancing formulary placements, and leveraging targeted marketing efforts are critical strategies to amplify adoption.
References
[1] Market Research Future, “Neuropathic Pain Market Forecast,” 2022.
[2] IQVIA Institute, “The Changing Landscape of Pain Management,” 2021.
More… ↓
